Anaemia and early phase cardiovascular events on haemodialysis

Nephrology

Volumn 20, Issue , 2015, Pages 1-6

  Hayashi, Toshihide ^a   Joki, Nobuhiko ^a   Tanaka, Yuri ^a   Hase, Hiroki ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

anaemia; cardiovascular disease; chronic kidney disease; haemodialysis; left ventricular hypertrophy

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; ARTERIAL STIFFNESS; ARTERIOVENOUS FISTULA; BLOOD FLOW; CAPILLARY DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; END STAGE RENAL DISEASE; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HORMONE SYNTHESIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MENTAL STRESS; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; WORKLOAD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; HEART; KIDNEY FAILURE, CHRONIC;

ANEMIA; CARDIOVASCULAR DISEASES; HEART; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84952909823     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12642     Document Type: Review

References (50)

1. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al., Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J. Am. Soc. Nephrol. 2003; 14: 3270-7.
2. Moroi M, Tamaki N, Nishimura M, et al., Association between abnormal myocardial fatty acid metabolism and cardiac-derived death among patients undergoing hemodialysis: results from a cohort study in Japan. Am. J. Kidney Dis. 2013; 61: 466-75.
3. Foley RN, Parfrey PS, Sarnak MJ,. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998; 9 (12 Suppl): S16-23.
4. Ronco C, McCullough P, Anker SD, et al., Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 2010; 31: 703-11.
5. Kazory A, Ross EA,. Anemia: the point of convergence or divergence for kidney disease and heart failure? J. Am. Coll. Cardiol. 2009; 53: 639-47.
6. Silverberg D,. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol. Dial. Transplant. 2003; 18 (Suppl 2): ii7-12.
7. Joki N, Hase H, Nakamura R, Yamaguchi T,. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol. Dial. Transplant. 1997; 12: 718-23.
8. Ohtake T, Kobayashi S, Moriya H, et al., High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J. Am. Soc. Nephrol. 2005; 16: 1141-8.
9. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 2005; 45 (4 Suppl 3): S1-153.
10. De Vriese AS, Vandecasteele SJ, Van den Bergh B, De Geeter FW,. Should we screen for coronary artery disease in asymptomatic chronic dialysis patients? Kidney Int. 2012; 81: 143-51.
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
12. Bradbury BD, Fissell RB, Albert JM, et al., Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin. J. Am. Soc. Nephrol. 2007; 2: 89-99.
13. Eckardt KU, Gillespie IA, Kronenberg F, et al., ARO Steering Committee. High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney Int. 2015. DOI: 10.1038/ki.2015.117 [Epub ahead of print].
14. Jungers P, Choukroun G, Robino C, et al., Epidemiology of end-stage renal disease in the Ile-de-France area: a prospective study in 1998. Nephrol. Dial. Transplant. 2000; 15: 2000-6.
15. Collins AJ, Li S, St Peter W, et al., Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J. Am. Soc. Nephrol. 2001; 12: 2465-73.
16. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ,. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am. J. Kidney Dis. 2002; 40: 1153-61.
17. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW,. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984; 25: 437-44.
18. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J,. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 2002; 162: 1401-8.
19. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ,. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-9.
20. Vlagopoulos PT, Sarnak MJ,. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med. Clin. North Am. 2005; 89: 587-611.
21. Levin A, Thompson CR, Ethier J, et al., Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am. J. Kidney Dis. 1999; 34: 125-34.
22. Wang H, Liu J, Yao XD, et al., Multidirectional myocardial systolic function in hemodialysis patients with preserved left ventricular ejection fraction and different left ventricular geometry. Nephrol. Dial. Transplant. 2012; 27: 4422-9.
23. Zoccali C, Benedetto FA, Mallamaci F, et al., Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65: 1492-8.
24. Glassock RJ, Pecoits-Filho R, Barberato SH,. Left ventricular mass in chronic kidney disease and ESRD. Clin. J. Am. Soc. Nephrol. 2009; 4 (Suppl 1): S79-91.
25. Horina JH, Schwaberger G, Brussee H, Sauseng-Fellegger G, Holzer H, Krejs GJ,. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol. Dial. Transplant. 1993; 8: 1219-22.
26. Duke M, Abelmann WH,. The hemodynamic response to chronic anemia. Circulation 1969; 39: 503-15.
27. Franchitto N, Despas F, Labrunée M, et al., Tonic chemoreflex activation contributes to increased sympathetic nerve activity in heart failure-related anemia. Hypertension 2010; 55: 1012-17.
28. Franchitto N, Despas F, Labrunee M, et al., Cardiorenal anemia syndrome in chronic heart failure contributes to increased sympathetic nerve activity. Int. J. Cardiol. 2013; 168: 2352-7.
29. Asakawa T, Joki N, Tanaka Y, et al., Association between the hemoglobin level and cardiothoracic ratio in patients on incident dialysis. Cardiorenal Med. 2014; 4: 189-200.
30. Kiyosue A, Hirata Y, Ando J, et al., Relationship between renal dysfunction and severity of coronary artery disease in Japanese patients. Circ. J. 2010; 74: 786-91.
31. Rostand SG, Kirk KA, Rutsky EA,. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984; 25: 653-9.
32. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE,. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996; 49: 1428-34.
33. Herzog CA, Asinger RW, Berger AK, et al., Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80: 572-86.
34. Cerasola G, Nardi E, Palermo A, Mulè G, Cottone S,. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J. Nephrol. 2011; 24: 1-10.
35. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F,. Cardiac consequences of hypertension in hemodialysis patients. Semin. Dial. 2004; 17: 299-303.
36. Lõpez B, González A, Hermida N, Laviades C, Díez J,. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int. Suppl. 2008; 111: S19-23.
37. Amann K, Breitbach M, Ritz E, Mall G,. Myocyte/capillary mismatch in the heart of uremic patients. J. Am. Soc. Nephrol. 1998; 9: 1018-22.
38. Iwasaki M, Joki N, Tanaka Y, et al., Declining prevalence of coronary artery disease in incident dialysis patients over the past two decades. J. Atheroscler. Thromb. 2014; 21: 593-604.
39. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD,. Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Nat. Rev. Cardiol. 2012; 9: 620-33.
40. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B,. TOTAL-AMI study group. Type 2 myocardial infarction in clinical practice. Heart 2015; 101: 101-6.
41. Saaby L, Poulsen TS, Hosbond S, et al., Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am. J. Med. 2013; 126: 789-97.
42. Anagnostou A, Liu Z, Steiner M, et al., Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 3974-8.
43. Cai Z, Manalo DJ, Wei G, et al., Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79-85.
44. Parsa CJ, Matsumoto A, Kim J, et al., A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003; 112: 999-1007.
45. Moon C, Krawczyk M, Ahn D, et al., Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 11612-7.
46. Shiojima I, Sato K, Izumiya Y, et al., Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 2005; 115: 2108-18.
47. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K,. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006; 47: 887-93.
48. Sano M, Minamino T, Toko H, et al., p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 22 (446): 444-8.
49. Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T,. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am. J. Physiol. Heart Circ. Physiol. 2009; 296: H585-93.
50. Asaumi Y, Kagaya Y, Takeda M, et al., Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007; 115: 2022-32.